Pointe Capital Management LLC Sells 21 Shares of Eli Lilly and Company (NYSE:LLY)

Pointe Capital Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,196 shares of the company’s stock after selling 21 shares during the quarter. Pointe Capital Management LLC’s holdings in Eli Lilly and Company were worth $923,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. AMF Tjanstepension AB lifted its stake in shares of Eli Lilly and Company by 113.7% in the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the last quarter. Values Added Financial LLC boosted its stake in Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after buying an additional 17 shares during the period. Cavalier Investments LLC lifted its holdings in shares of Eli Lilly and Company by 211.1% in the 3rd quarter. Cavalier Investments LLC now owns 32,556 shares of the company’s stock worth $28,843,000 after acquiring an additional 22,090 shares during the last quarter. Peterson Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 8.5% during the 3rd quarter. Peterson Wealth Advisors LLC now owns 716 shares of the company’s stock worth $634,000 after purchasing an additional 56 shares during the period. Finally, Kercheville Advisors LLC grew its holdings in Eli Lilly and Company by 10.3% during the 3rd quarter. Kercheville Advisors LLC now owns 8,540 shares of the company’s stock valued at $7,566,000 after purchasing an additional 795 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on LLY shares. Truist Financial boosted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Trading Up 2.4 %

Eli Lilly and Company stock opened at $902.47 on Wednesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $855.69 billion, a PE ratio of 77.07, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. The stock has a 50-day moving average of $805.87 and a two-hundred day moving average of $847.99. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 51.24%.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.